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Complex, Timely, and Necessary*Graeme J. Koelwyn, MSC,y Lee W. Jones, PHD,z Javid Moslehi, MDxSEE PAGE 1310T here are an estimated 14.5 million cancer sur-vivors in the United States, a number thatis expected to reach 19 million by 2024 (1).
Because of continued improvements in cancer-
speciﬁc mortality, cancer survivors are at an in-
creased risk of competing causes of morbidity and
mortality, particularly, cardiovascular toxicity. As
such, there is a growing need to deﬁne and under-
stand the chronic and late cardiovascular effects of
cancer and its therapeutic approaches.
Following a cancer diagnosis, and dependent on
the selected treatment course, patients are subjected
to a series of direct or indirect pathological pertur-
bations that can damage 1 or more of the components
of the pulmonary, cardiovascular, hematological, and
musculoskeletal systems (Figure 1). The gold standard
assessment of the maximal efﬁciency of these sys-
tems to integratively transport oxygen (O2) from the
atmosphere into metabolically active mitochondria
(termed the O2 cascade) is maximal (VO2max) or peak
(VO2peak) oxygen consumption. Therefore, marked
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this cannot be understated. Poor VO2peak is a robust,
independent predictor of cardiovascular and all-
cause mortality, and it provides powerful risk strati-
ﬁcation and/or clinical decision-making information
in numerous clinical settings (2,3). Thus, character-
izing the magnitude of exercise intolerance in
patients diagnosed with cancer and why cancer
patients exhibit marked impairments in VO2peak is
timely and important. Such endeavors elucidate how
cancer and anticancer therapies affect the underlying
determinants of VO2peak.In this issue of the Journal, Cramer et al. (4) eval-
uate the level of exercise intolerance and factors
associated with the magnitude of intolerance in a
cross-sectional cohort of 50 patients with colorectal
cancer (CRC), 51 patients with heart failure, and
51 healthy control subjects. Exercise tolerance was
assessed using a treadmill protocol to symptom lim-
itation with metabolic gas exchange measurement to
assess VO2peak. Intriguingly, the investigators found
that, on average, CRC patients had a mean VO2peak of
21.8 ml/kg/min, equivalent to 23% below that of the
age-matched control subjects (mean 28.0 ml/kg/min),
and that VO2peak was only approximately 17% higher
than that of the heart failure patients in the study.
The marked impairment in VO2peak corroborates work
by other investigators who showed that patients with
various solid or hematological malignancies have
marked reductions in VO2peak (5,6). This is an
intriguing ﬁnding, because it can be anticipated that
exercise tolerance is relatively normal since CRC
patients do not receive anticancer therapies that are
traditionally expected to signiﬁcantly impair 1 or
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FIGURE 1 Postulated Mechanisms Leading to Reduced Peak Oxygen Consumption (VO2peak) Following a Cancer Diagnosis
Direct and indirect treatment effects can lead to signiﬁcant reductions in VO2peak via impairments in 1 or more of the steps within the oxygen
cascade (i.e., the pulmonary, cardiovascular, hematologic, and musculoskeletal systems). Impairments in 1 or more of these steps directly
affects VO2peak via changes in the components of the Fick equation (3), where the VO2 is equal to the product of cardiac output and arte-
riovenous O2 content difference (a-vO2).
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1321more of the components of the O2 cascade (e.g., im-
paired pulmonary diffusion associated with thoracic
surgery, cardiotoxicity associated with anthracyclines
or human epidermal growth factor receptor (HER2)
targeted therapies, skeletal muscle myopathy caused
by androgen deprivation therapy). To provide insight
into the potential underlying causes of the observed
impairments in VO2peak, Cramer et al. (4) explored a
total of 18 medical and physiological predictors.
Of these, hemoglobin, lean mass (leg and whole
body), maximal heart rate on exercise, heart rate
variability, and the blood biomarker, endothelium-
derived C-terminal-pro-endothelin-1, were signiﬁ-
cant predictors of VO2peak. These ﬁndings provide
new insight into factors that may affect the integra-
tive reserve of the O2 cascade that contributes to theobserved reductions in exercise tolerance. However,
how some of these factors contribute to impairments
in the major determinants of VO2peak remains to be
elucidated. Speciﬁcally, VO2 is determined by the
Fick equation, where the VO2 is equal to the product
of cardiac output and the arteriovenous O2 content
difference (a-vO2) (3). Impairments in 1 or more of the
steps within the O2 cascade that lead to a reduction in
either cardiac output and/or a-vO2 will predictably
and proportionally reduce VO2peak (3). Although
Cramer et al. (4) unfortunately did not speciﬁcally
measure cardiac output or a-vO2, the assessment of
parameters such as hemoglobin concentration (an
important component of the O2 cascade) were per-
formed. Reductions in hemoglobin would directly
affect convective O2 delivery by a proportional
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1322reduction in the content of arterial O2 deliverable to
the active muscle, which leads to impaired VO2peak.
Based on the ﬁndings of Cramer et al. (4), the critical
next step of investigation is to understand how CRC
and its associated therapies affect cardiac output and/
or a-vO2, as well as steps in the O2 cascade that lead to
impairments in VO2peak. As in other clinical pop-
ulations, the causes of exercise intolerance in CRC
patients is likely multifactorial, with no single organ
component being the cause of limitation (3). This
particularly may be the case in the study by Cramer
et al. (4), because the patient cohort was heteroge-
neous with regard to disease stage, treatment status,
and type of previous and current anticancer therapy.
As previously reviewed by our group (7), the direct
effects of surgery, combination chemotherapy, radio-
therapy, and antiangiogenic therapy, combined with
the effects secondary to treatment (aging, decondi-
tioning), may all affect the convective and diffusive
steps in the O2 cascade to varying degrees. Although
challenging to conduct, recruitment of cancer cohorts
that are homogenous in terms of disease stage and
treatment exposure(s), as well as other confounding
factors, are optimal to fully elucidate the effect of a
given anticancer therapy on VO2peak and its primary
underlying mechanism of action. Such efforts, in turn,
will inform the design of limitation-driven therapeutic
strategies to prevent and/or recover poor VO2peak.
Aerobic training is arguably the most effective
strategy to improve VO2peak because it improves
the integrative reserve of the cardiovascular and
musculoskeletal systems (8). Randomized trials have
demonstrated that aerobic training is associated with
signiﬁcant improvements in VO2peak in patients with
early-stage cancer with minimal adverse events (9).
The adaptations associated with aerobic training are
well established in healthy individuals (3). However,
whether aerobic training causes similar adaptations
or how aerobic training affects the sequential stepswithin the O2 cascade in patients with cancer has not
been investigated. This is a major research gap,
because elucidation of these complexities are essen-
tial to optimize the safety and efﬁcacy of exercise
prescriptions in the oncology setting. Furthermore,
by elucidating the limitations to exercise in cancer,
prescriptions can be optimized that focus on
reversing and/or mitigating the speciﬁc perturbations
caused by cancer and its associated therapy.
The ﬁndings of Cramer et al. (4) highlight a key
opportunity in the emerging ﬁeld of cardio-oncology.
To date, the majority of work in this ﬁeld has focused
exclusively on the cardio-centric toxicity associated
with cancer therapy. It is clear, however, that reduced
VO2peak may be a new hallmark of both the cancer itself
and the cancer therapy-associated toxicity that is the
result of the acute and late effects of therapy. Such
impairment is apparent even in the absence of
impaired cardiac function (at least when measured by
conventional parameters such as left ventricular
ejection fraction), suggesting that cardio-oncology
specialists may need to think more broadly and
consider incorporation of techniques such as cardio-
pulmonary exercise testing, which provides in-
formation that extends beyond the heart when
characterizing, monitoring, and managing cancer
therapy late effects. Such considerations may facili-
tate treatment stratiﬁcation, mortality risk prediction,
and surveillance of therapy-induced toxicity and/or
recovery across the cancer survivorship continuum.
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